Abstract Background and purpose: Combined PET/CT using 18F-FDG is widely used in evaluation of various malignancies; in their initial staging and more efficiently in their follow up; hence, the importance of evaluation of its diagnostic role in the imaging of skeletal metastases. The purpose of this study is to evaluate precisely the efficiency of FDG PET/CT in detection and characterization of osseous metastatic lesions compared to isolated PET and CT in various malignancies. Patients and methods: The study included 123 patients divided into seven groups of malignancies to whom PET/CT was done. In this study population, a detailed retrograde lesion based analysis was performed for a total of 1705 detected bone lesions on PET, CT and fused PET/CT images. Sensitivity, specificity, PPV and NPV of each modality were calculated. Semi-quantitative and ROC curve analysis of the lesions were performed to study the relationship between the lesion's SUV and its corresponding morphologic pattern on CT and to set a reliable SUV max cut-off value that can predict the presence of malignant lesion. Results: The calculated fused PET/CT sensitivities and specificities in various malignancies ranged from 95.2% to 99.6% and 75% to 100%, respectively. The combined PET/CT has significantly improved the low CT sensitivity (especially in lymphoma) as well as both CT and PET specificities. 
Introduction
Positron emission tomography (PET) is a molecular imaging technique most widely applied in oncology, using 18F labeled fluorodeoxyglucose (18F-FDG). It provides quantitative and qualitative functional information about tumor cells depending on their increased rate of glucose metabolism. 18F-FDG PET is regarded to be effective in the detection, staging and restaging of malignancies with a remarkably high sensitivity. The combination of PET and computed tomography (CT) represents a very unique imaging modality that scans the whole body in the same session, providing functional and anatomic information in coregistered images. It combines the high sensitivity of PET to the superior anatomical localization by CT resulting in much more accurate detection and staging of malignancies (1) .
Several studies had illustrated the additional value of PET/ CT scan compared to various imaging modalities in the accurate initial staging and follow up of malignancies. PET/CT scan is able to identify invisible metastatic lesions not yet developing into structural changes. Thereby, a significant change in the management plan might be done (2) .
Combined PET/CT is widely applied in the evaluation of various malignancies; hence the importance of evaluating its role in the detection and characterization of skeletal metastases. The integration of PET and CT in one modality has improved the diagnostic accuracy of each in the evaluation of malignancies and nevertheless in the evaluation of skeletal metastases (1).
Patients and methods
The study population included 123 cancer patients (57 male patients, 66 female patients; mean age: 43.3; age range: 14-85) who underwent whole body combined PET/CT scanning. The indications for PET/CT examination were variable; 15 patients were referred for initial disease staging and 108 patients for follow up at variable disease stages.
We have divided the study population into groups according to the type of primary malignancies for more accurate data analysis. For all patients, the primary malignancy type has been pathologically proven.
The study excluded those who had recent intervention (biopsy) or local external beam radiotherapy or granulocyte colony stimulating factor therapy within 1 month from PET/ CT scan.
PET/CT technique
Combined PET/CT scan was performed using Siemens Biograph TruePoint 64; (Siemens Healthcare, Erlangen, Germany). The integrated CT system is a 64 multi-slice scanner. The acquisition of co-registered CT and PET images was performed in one session.
Adequate patient preparation rules were strictly followed. Patients were instructed to fast except for glucose-free hydration for 4-6 h before injection of 18F-FDG. The scan was performed 40-60 min after IV injection of 3.7 MBq/kg; (maximum dose 370 MBq) equivalent to 0.1 mCi/kg; (maximum dose = 10 mCi) of 18F-FDG. The patients were examined in supine position. A whole body examination was performed starting from skull base to mid thighs.
A PET emission scan was performed over several bed positions (5-7), each with an axial field of view of approximately 15 cm per bed position with an in-plane spatial resolution of 4 mm covering the same field of view as with CT. The acquisition time of emission data was 2 min per bed position in the two dimensional mode. The total examination time range was between 13 and 17 min. A fully diagnostic CT scan was performed using the following parameters: 350 mA, 120 kV, 0.5 s tube rotation time, slice thickness 5 mm, 8-mm table feed and 3 mm incremental reconstruction. IV contrast administration (80-120 mL of a low-osmolarity iodinated contrast agent (Ultravist 300 Ò ,Schering, Berlin, Germany) and negative oral contrast agent (water) for bowel were used.
Images were reconstructed and viewed on workstation (Syngo Multimodality Workplace, Siemens Medical Solutions), which provided multi-planar reformatted PET, CT and fused PET/CT images with linked cursors as well as 3D maximum intensity projection images (MIP) PET images in video mode.
Image analysis
The PET images were reviewed by one experienced nuclear medicine physician. The CT images were analyzed separately by two experienced radiologists; each was blind to the other's findings. Fused PET/CT images were then analyzed separately by each of the three. In case of CT images, if the recorded findings or estimated score by the two radiologists were not the same, they had to reach a consensus together. While for fused PET/CT images, if the interpreted findings by any of the three readers were not the same, we approved the opinion agreed upon by at least two of them.
The presence of bone metastases was confirmed by biopsy or sequential various imaging modalities including CT, PET/ CT, magnetic resonance imaging (MRI); performed during a follow up of at least 6 months. In some cases reviewing previous scans was also done to correlate recorded lesions.
PET images
Analysis of PET images was done via visual and semi quantitative assessment (SUV max measurement). Positive lesions were recorded at areas of high FDG uptake. The standardized uptake value (SUV max ) was measured at each lesion and compared to background activity. The standard background activity was measured at the liver, right lobe. In patients having diseased liver, the background activity was measured at the mediastinal blood pool. Accordingly a scoring system was applied (Table 1) .
At final diagnosis, true positive lesions were those with PET score >3 and confirmed as active bone metastases by biopsy or on follow up imaging (whether they show a corresponding morphologic changes on CT or not). Lesions with score 2 or 3, or have been missed on current scan and proved to be malignant as evidenced by progression on follow up images, were considered false negative. Lesions which have been missed being outside PET/CT scan field and detected on other imaging modalities were also considered false negative.
PET recorded lesions were considered false positive if uptake has been localized extra-osseous on corresponding fused PET/CT images or a lesion with score >3 appeared to be benign on fused PET/CT images or other imaging modalities and confirmed by biopsy or on further follow up images. True negative lesions were those lacking appreciable uptake on PET (score 1), though looking malignant on corresponding CT images, and confirmed as healed inactive lesions when correlated to previous scans and follow up images and lesions with score 63 and proved to be benign on fused PET/CT images or other imaging modalities and confirmed on further follow up images.
CT images
The whole CT images were reviewed in bone as well as soft tissue windows. Detected areas of abnormal FDG uptake on PET images were, in particular, further analyzed on CT images. Bone lesions were classified into benign and malignant looking lesions according to their morphologic appearance. Some lesions which did not meet the criteria of either were considered equivocal. Accordingly, a scoring system was also performed for the lesions (Table 2) .
Bone lesions were considered benign according to the following criteria: being well defined, homogenously and fully sclerotic, and lytic with regular sclerotic margins. Localization to the vertebral end plates or articular surfaces was also considered a benign feature.
Bone lesions were considered malignant if appeared ill defined, irregularly or heterogeneously sclerotic, lytic with irregular sclerotic margins, associated with cortical destruction or extra osseous soft tissue component.
At final diagnosis, true positive lesions were those assigned as score 4 and confirmed as active bone metastases by biopsy or on follow up imaging. Lesions with score <4 or have been missed on current scan and proved to be malignant on follow up images, were considered false negative. Lesions with score 1 which show uptake on corresponding fused PET/CT images and proved to be malignant by biopsy or on follow up images were also considered false negative lesions.
The CT recorded lesions were considered false positive if a malignant looking lesion (score 4) did not show appreciable uptake on corresponding fused PET/CT images and proved to be a healed inactive bone metastasis when correlated to previous scans and follow up images. True negative lesions were those with score 2 or 3 and proved to be benign on follow up imaging.
Fused PET/CT images
On interpreting fused PET/CT images, lesions were considered positive (active bone metastases) when areas of increased FDG uptake (>liver or mediastinal blood pool) are localized to bone whether showing corresponding morphologic changes or not. Lesions were considered negative for active bone metastases at areas lacking high FDG uptake (6liver or mediastinal blood pool) despite suspicious corresponding CT findings if any.
At final diagnosis, true positive lesions were those recognized as active metastases and confirmed by biopsy or on follow up imaging. Lesions which have been missed on current scan and proved to be malignant on follow up images were considered false negative. Lesions which have not been recorded, being outside the scan field (e.g. calvarial bones or at the extremities), were also considered false negative lesions.
Fused PET/CT recorded lesions were considered false positive if a lesion has been considered as active metastasis and proved to be benign by biopsy or follow up imaging. True negative lesions were those recognized as benign lesions and confirmed so by different imaging modalities on follow up imaging. Also lesions which have been recognized as inactive healed metastases and confirmed when correlated to previous scans and follow up imaging were also considered true negative lesions.
Statistical analysis
Data were tabulated and digitalized on a personal computer using Microsoft Excel for Mac version 14.0.0 spreadsheet program. Discrete data are presented as mean ± standard deviation. Categorical data are presented as percentage. Descriptive statistics, calculation of the true and false positive 
Results
The study included 123 patients (57 male patients, 66 female patients). Their age range is 14-85 years; with mean age: 43.3 years ± 16.22 (SD). The study population composes 7 groups of different primary malignancies (Table 3 ). All the bone lesions (1705 lesions) were separately analyzed on PET, CT and fused PET/CT images in each of the 7 groups (Fig. 1) . According to the designed PET scoring system, all lesions with score 4 or 5 were considered positive for metastases. According to the designed CT scoring system, all lesions with score 4 were considered positive for metastases.
Tables 4-6 demonstrate the number of true positive (TP), true negative (TN), false positive (FP) and false negative (FN) lesions as well as the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for PET, CT and combined PET/CT, respectively.
Five false negative lesions on PET, CT and fused PET/CT images were bone metastases that have been missed being outside the scan field (e.g. at the skull bones and at the long bones peripherally) and have been detected by other imaging modalities.
On PET images, the false negative lesions also included lesions of low to moderate metabolic activity (score 63). False positive lesions on PET images included benign bone lesions of high metabolic activity (score >3) (e.g. fractures in acute stage) and focal areas of intense uptake at soft tissue in close proximity to bone and misinterpreted as bone metastases due to lack of proper anatomical localization (e.g. metabolically active lymph nodes adjacent to vertebrae). For such false positive PET lesions, fused PET/CT images was much more helpful, it accurately detected extra osseous uptake guided by anatomical localization on CT images with no confusion.
On CT images, there was a considerably large number of missed (false negative) lesions due to absence of any detectable structural abnormalities, however, a high metabolic activity of such lesions allowed their proper detection on fused PET/CT images. Almost all of the false positive lesions on CT images were malignant looking (score 4) while being metabolically inactive (absent FDG uptake on PET and fused PET/CT images) representing healed bone metastases.
Fused PET/CT images had much less false results compared to either of its components alone. Fused PET/CT images missed lesions which were located outside the routine PET/CT scan field and those were few and were not solitary metastasis. In our study, false positive lesions on fused PET/CT images were bone fractures in their acute stage, these had shown a high metabolic activity (measured SUV max was higher than the background uptake).
Fused PET/CT images allowed accurate localization of uptake (osseous versus extra osseous), identification of healed bone metastases as such by the absence of uptake as well as allowed detection of early bone marrow infiltration before structural changes are apparent on CT images.
The sensitivity of PET ranged from about 86% to 98%. It was lowest in the breast cancer group due to the presence of considerably large number of false negative lesions (n = 47), 4 lesions outside the scan field and 43 missed lesions with score 3. These 43 lesions have progressed in the follow up studies. The specificity of PET ranged from about 25% to 95%. It was lowest in the colon cancer group due to the presence of relatively large number of false positive lesions (n = 6 out of 75), 4 misinterpreted lesions as bone metastases while being nearby metabolically active nodal and pleural deposits and 2 benign lesions (one was a rib fracture and the other was a vertebral body wedge fracture in acute phase with score >3).
The sensitivity of CT ranged from about 7% to 95%. It was lowest in the Non Hodgkin's lymphoma and Hodgkin's disease (NHL and HD) groups due to the presence of considerably large number of false negative lesions (n = 238 and 447). The vast majority of these lesions showed no structural CT abnormalities (Fig. 2) . The specificity of CT ranged from about 25% to 100%. It was lowest in the breast cancer group due to the presence of relatively large number of false positive lesions (n = 145 out of 526), all were malignant looking (score 4) while being metabolically inactive, absent FDG uptake on PET, and proved to be healed metastases. The highest CT sensitivity (95%) was noted in the bronchial cancer group, while the highest CT specificity (100%) was noted in the bronchial, renal and colon cancer groups where no false positive lesions were interpreted on CT.
The combined PET/CT showed the highest sensitivity in all of the 7 groups compared to isolated PET and CT, ranging between 95.2% and 99.6% (Fig. 3) . The specificity of fused PET/ CT was also high ranging from 75% to 100%. It was lowest in the colon cancer group due to the presence of 2 false positive lesions for benign fractures when their high metabolic activity was considered despite of their CT appearance. The highest PET/CT specificity (100%) was noted in the bronchial, renal cancer (Fig. 4) and HD groups.
We performed a semi-quantitative analysis of lesions detected on PET/CT. SUV max has been measured for each lesion. The relationship between the lesion's SUV and its corresponding morphologic pattern on CT has been studied. We found Fig. 1 Number of confirmed active bone metastasis in each group compared to the total number of analyzed lesions. that the lesions of highest SUV max were the lytic bone lesions followed by those of absent morphologic changes. The lesions of lowest SUV max were the sclerotic lesions. The bone lesions of mixed patterns lied in between (Fig. 5) . Furthermore, the cut-off value of the SUV max that can predict the presence of malignant lesion was evaluated by the ROC curve analysis.
It has been shown that both an SUV max > 2 and >3 have high sensitivity to detect malignant lesions (99.7% and 97%, respectively); however with a higher specificity if the cut-off value was set at 3 (69.4% versus 54.2%). Both values have shown a high positive and negative predictive values and a very low bias index. On further follow up, sclerosis has increased with no corresponding FDG uptake but a newly developed metabolically active lesion at the right pedicle is noted.
Discussion
The study population included a total number of 123 cancer patients. A total number of 1705 bone lesions were separately analyzed on PET, CT and fused PET/CT images. At final diagnosis, 1355 were confirmed to be actual bone metastases. We performed a separate analysis for data interpreted on PET, CT and fused PET/CT images in order to evaluate and compare the diagnostic accuracy of each imaging modality and evaluate the added value of combined PET/CT imaging in the detection and characterization of metastatic bone lesions. Although many studies had evaluated the diagnostic accuracy of FDG-PET in bone metastases (3) (4) (5) (6) (7) (8) , few had performed such a comparative analysis for the three components in the same study especially regarding the evaluation of CT scan alone (9, 10) . We preferred to analyze the data separately in each primary malignancy for a better insight into the nature of each primary malignancy respecting their different behavior and metabolic activity. The performed CT scoring system in our study categorized the detected lesions according to the diagnostic possibilities (either malignant or not) to obtain a more accurate evaluation of the efficiency of CT in the characterization of lesions in oncology patients. The PET scoring system categorized the lesions according to their visually inspected uptake in comparison to the background uptake and then only those with detectable uptake higher than that of the background were considered definitely malignant. Accordingly, a considerable number of metabolically active bone metastases were missed and have been considered false negative thereby underestimating PET sensitivity. That is why it is worth to mention that when bone lesions having a PET score P3 also recorded as positive; the estimated PET sensitivity was higher but on the expense of lowering PET specificity. The same was also true for equivocal bone lesions having a CT score 3. Recording such lesions as positive increases the sensitivity of CT but on the expense of lowering the specificity.
The routine PET/CT scan field covers the skull base down to mid thighs. This resulted in missing few metastatic bone lesions (4 in breast cancer and 1 in NHL patients groups) located at the skull calvarium and femoral condyles. It is noted that these lesions were not the only metastatic bone lesions in the studied patients and here we agree with Fujimoto et al. (5) that such a limitation is not a major drawback, however, it may be wise to extend the scan field to cover the skull especially in breast cancer patients where skull metastases are rather more common.
In our study, CT shows low sensitivity in the detection of bone metastases, explained by the large number of bone metastases which do not show morphologic changes. This was especially true in lymphoma patients, where the estimated CT sensitivities were 6.89% and 17.52% in HD and NHL patients respectively. The integration of PET and CT has notably improved the sensitivity of CT through detection of high FDG uptake by bone marrow based metastatic cells which are not associated with structural bone changes; neither destructive nor osteoblastic. This goes in concordance with the results of previous studies. Nakamato et al. (11) stated that among true positive bone metastases seen at PET, morphologic changes at CT were observed in only half. Evangelista et al. (12) also stated that PET/CT yielded accurate results in the early detection of bone marrow metastases in breast cancer, lymphoma as well as multiple myeloma. Schaefer et al. (13) also encouraged the superiority of PET/CT compared to CT alone or in combination with bone marrow biopsy in lymphoma. The bronchial cancer group was the only exception in our study where the estimated CT sensitivity is 95.28%. This is actually because all the analyzed bone lesions in this small group of patients had corresponding structural changes either of lytic or mixed pattern.
Regarding CT specificity, almost all false positive lesions on CT images in our study were in fact healed metastases. This was more evident in breast cancer patients, where a large number of this group population was referred for follow up at a regressive disease course explaining the notable low specificity of CT (24.87%) and high specificity of PET (95.33%) in this group. Here the integration of PET and CT significantly improved the specificity of CT and the accuracy of diagnosis through identifying metabolic inactivity regardless the suspicious or malignant looking CT appearance. We agree with Tiara et al. (14) emphasizing the influence of chemotherapy on the PPV of PET and CT interpretation and the importance of prior knowledge of treatment history. The calculated specificity of CT images alone was 100% in the colon cancer, renal cancer and bronchial cancer groups. It perfectly localized FDG uptake to bone and could identify all benign lesions in these groups. This was a perfect performance compared to the much lower calculated CT specificities in the other groups reflecting the difference in the number of patients in each group and the number of the analyzed bone lesions with a subsequent higher possibility of false positive results in larger groups especially in patients having variably healed metastatic lesions.
Regarding the calculated CT versus combined PET/CT specificities in colon cancer patients, we would like to explain why that of PET/CT was exceptionally lower than CT. This was because of two benign lesions which were accurately detected as benign (negative) on CT alone, however according to our methodology we considered lesions with higher uptake than the background to be positive on fused PET/CT ignoring their morphologic CT criteria.
The results of our study agree with the results of previous studies by Yang et al. (9) and Liu et al. (10) in showing that CT as an imaging modality is more specific than sensitive and that its integration with PET in combined PET/CT improved both its sensitivity and specificity; however variable the calculated figures are. Yet such improved performance by combined PET/CT is more notable in our results.
We would like to elaborate that a variety of benign lesions have been analyzed in our study, including vertebral body haemangiomata, osteoid osteoma, schmorl's nodes, fractures, spondylosis, osteoarthritis, avascular necrosis, bone cyst and bone islands. All these lesions were correctly identified on CT. On the other hand, PET was false positive in 3 rib fractures in the breast cancer patients group, 3 rib fractures in the NHL patients group, 1 rib and 1 vertebral body fractures in the colon cancer patients group and in periprosthesis inflammatory/infective process in a case of osteosarcoma. In our study, we relied on the recorded FDG uptake value (SUV max ) considering those more than the liver as positive at both PET and fused PET/CT images, ignoring other criteria of uptake (e.g. being diffuse or focal) and their corresponding CT appearance. That was the source of false interpretation of these benign lesions (false positive results) on PET and fused PET/CT images. According to our experience in the studied lesions, we found that considering the CT criteria of these lesions will largely eliminate false results. In fact all falsely recorded benign lesions in our study on PET and fused PET/CT images were identified as benign on CT component regardless their uptake value. Lack of bony expansion and soft tissue components on CT images strongly predicted the benign Fig. 5 The relationships between SUV max of bone lesions on PET and their corresponding morphologic pattern on CT.
nature of these lesions with the latter better appreciated on soft tissue windows. We agree with Shin et al. (15) in his study showing a pathological fracture as having central medullary high uptake. In our study, falsely recorded benign fractures as malignant, though having high FDG uptake higher than the liver, yet such uptake was linear and diffuse rather than focal in appearance and largely cortical rather than medullary.
These benign lesions with high uptake were not the only source of false positive PET lesions. In fact a major source of false positive PET lesions was focal uptake at soft tissue lesions in close proximity to bone. These were frequently encountered in all studied groups, yet most numerous in lymphoma (HD > NHL) due to nodal involvement in close proximity to the vertebrae. The prevalence of such false positive lesions in different groups reflects the variable calculated PET specificities being least in colon, renal and bronchial cancer groups (25%, 33.33% and 50%, respectively) having the least number of analyzed lesions. The breast cancer group was an exception in showing a much higher calculated PET specificity (95.33%) attributed to the large number of metabolically inactive healed metastases recorded as true negative while having suspicious malignant looking CT appearance.
The results of our study show that PET had variably high sensitivities ranging from 85.88% to 98.41%; these figures are much higher compared to CT sensitivities but are slightly less than or even equal to fused PET/CT sensitivities. Yet the integration of PET and CT notably improved PET specificities in all groups. The previous studies also had similar results regarding the high estimated PET sensitivities as in Chang et al. (19) . These studies also showed a similar improved specificity for combined PET/CT compared to PET alone.
According to the results of our study, the interpretation of fused PET/CT images had overall more accurate results than the interpretation of PET or CT images alone. The estimated PET/CT sensitivities in different groups ranged from 95.23% to 99.63% while the estimated PET/CT specificities in different groups ranged from 95.16% to 100%. In fact the integration of PET/CT greatly improved the sensitivity of CT and the specificity of PET. Fused PET/CT images will have almost perfect results when considering the integrated information from both modalities PET and CT and especially respecting CT criteria regardless the FDG uptake value in evaluating likely benign osseous lesions.
We studied the relationship between FDG uptake and the morphologic nature of bone lesions. A semi quantitative analysis was performed through measuring SUV max at each lesion. Lesions having highest average values of SUV max were lytic bone metastases (8.42) followed by those of no corresponding morphologic changes (8.37). Sclerotic bone metastases showed lower average values of SUV max (2.37). Sclerotic bone metastases were detectable on PET/CT scan, though showing lower values of FDG uptake yet appreciable visible uptake is noted. The integration of PET and CT further limits the possibility of missing such lesions being readily visible on CT images. We agree with Koolen et al. (20) that it is not so much the type of metastasis (sclerotic or lytic), but possibly the characteristics of the primary tumor or treatments prior to the PET/CT scan might influence the degree of FDG uptake of bone metastases. We believe that lower SUV max by these lesions reflects lower metabolic activity of individual cancer lesions which in turn is associated with more osteoblastic reaction.
We also performed a ROC analysis for recorded SUV max at benign and malignant bone lesions as an attempt to estimate a cut off value. We found that the best diagnostic accuracies were obtained at SUV max 2 and 3 with sensitivities 99.7% and 97%, respectively and specificities 54.2% and 69.4%, respectively. In our opinion we prefer using SUV max 3 rather than 2 as a cut off value because of much improved specificity. The difference in the calculated sensitivities is rather small compared to the difference in their specificities and since the main limitation of PET is its specificity, we prefer using SUV max 3. In our study, we wanted to make the best of our analyzed data and to propose this as a guide in confusing cases. However as previewed literature (21) emphasized the importance of cautious use of any published cut off values, we also do. Yet this may be of value in some limited confusing cases. We also believe that the integration of PET and CT data interpretation largely limits the diagnostic challenge of benign versus malignant.
Conclusion
In combined PET/CT, CT images significantly improve PET specificity with better localization of bone metastases and differentiation between benign and malignant lesions. On the other hand, PET can detect bone marrow based metastases early and in the absence of morphologic changes on CT images; thereby improving CT sensitivity. The influence of the integration of PET and CT upon CT specificity is also notable in cases of treated healed metastases which lack metabolic activity in spite of suspicious morphologic appearance.
The estimated fused PET/CT sensitivities and specificities in our study population ranged from 95.2% to 99.6% and from 75% to 100%, respectively. The fused PET/CT sensitivities were higher than or equal to PET sensitivities but they were much higher than CT sensitivities especially in the lymphoma groups. The fused PET/CT specificities also showed variably higher values compared to PET and CT, emphasizing the important role of combined PET/CT in detection and characterization of bone lesions in cancer patients.
According to our ROC analysis, we suggest using SUV max 3 as a cut off value for malignant osseous lesions. However, it should be used with caution in some limited confusing cases.
